77300-51-7

Basic information

• Product Name: Pentanoic acid, 2-isocyanato-3-methyl-, methyl ester
• CAS NO: 77300-51-7
• Molecular Formula: C8H13NO3
• Molecular Weight: 171.196
• Mol File: 77300-51-7.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Pentanoic acid, 2-isocyanato-3-methyl-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Pentanoic acid, 2-isocyanato-3-methyl-, methyl ester(77300-51-7)
• EPA Substance Registry System: Pentanoic acid, 2-isocyanato-3-methyl-, methyl ester(77300-51-7)

Safety Data

• Hazardous Substances Data: 77300-51-7(Hazardous Substances Data)

Upstream product

• 2577-46-0 L-isoleucine methyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 75-44-5 phosgene 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 18598-74-8 methyl L-isoleucinate hydrochloride 
• 73-32-5 L-isoleucine 

Downstream Products

• 1013032-15-9 C₂₂H₃₂ClN₃O₃ 
• 3054-37-3 DL-isoleucine hydrochloride 
• 1013033-81-2 N-[[1-(4-chlorophenyl)-2-isopropyl-2,7-diazaspiro[3.5]non-7-yl]carbonyl]-L-isoleucine 

Relevant articles and documents

An Improved Method for the Synthesis of Enantiomerically Pure Amino Acid Ester Isocyanates

-

Design, synthesis and biological evaluation of novel amino acid ureido derivatives as aminopeptidase N/CD13 inhibitors

A series of amino acid ureido derivatives as aminopeptidase N (APN/CD13) inhibitors were synthesized and evaluated for their APN inhibitory activities and anti-cancer effects. The results showed that most of these amino acid ureido derivatives exhibited good inhibition against APN, several of which were better than Bestatin. The most active compound 12j (IC50 = 1.1 μM, compared with Bestatin IC50 = 8.1 μM) not only possessed much better APN inhibitory activity and anti-proliferation effect on cancer cells, but also exhibited significant block effect of human cancer cell invasion compared with the positive control, Bestatin. These amino acid ureido derivatives could be possibly developed as new APN inhibitors for cancer chemotherapy in the future.